Research Grade Etrolizumab (DHC98803)

Catalog No.

DHC98803

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Humanized

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

ITGA4, CD49d, CD49 antigen-like family member D, CD49D, VLA-4 subunit alpha, Integrin alpha-IV, Integrin alpha-4, Gut homing receptor beta subunit, Integrin beta-7, ITGB7

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P13612 & P26010

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

Anti-Beta7, PRO145223, RG7413, rhuMAb Beta7, CAS: 1044758-60-2

Clone ID

Etrolizumab

Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program, PMID: 32445184

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial, PMID: 24814090

Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins?, PMID: 31951748

Etrolizumab for ulcerative colitis: the new kid on the block?, PMID: 26914639

Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease, PMID: 30774593

Antibodies to watch in 2020, PMID: 31847708

Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease, PMID: 29601644

Etrolizumab for induction of remission in ulcerative colitis, PMID: 26630451

The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes, PMID: 27366219

Biologic agents for IBD: practical insights, PMID: 26284562

New treatment options for inflammatory bowel diseases, PMID: 29556726

Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: A systematic review and indirect comparison, PMID: 30395950

Anti-integrin therapy for inflammatory bowel disease, PMID: 29740202

Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More, PMID: 32570252

Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?, PMID: 28765121

Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances, PMID: 31127023

α 4 β 7 integrin inhibitors: a patent review, PMID: 30444683

Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis, PMID: 29178491

Etrolizumab in moderate-to-severe ulcerative colitis, PMID: 24814088

Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis, PMID: 26522261

AlphaE Expression in Inflammatory Bowel Disease: a Biomarker for the use of Etrolizumab?, PMID: 30418517

Etrolizumab in ulcerative colitis: tightening leukocyte traffic control in the inflamed mucosa, PMID: 25457851

Similar Inhibition of Dynamic Adhesion of Lymphocytes From IBD Patients to MAdCAM-1 by Vedolizumab and Etrolizumab-s, PMID: 29788362

Etrolizumab: anti-β7-a novel therapy for ulcerative colitis, PMID: 24269566

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis, PMID: 22717454

Comparable Pharmacokinetics, Safety, and Tolerability of Etrolizumab Administered by Prefilled Syringe or Autoinjector in a Randomized Trial in Healthy Volunteers, PMID: 33778929

An Open-Label Tolerability and Actual-Use Human Factors Study of Etrolizumab Autoinjector in Healthy Volunteers, PMID: 33778928

Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis, PMID: 30478492

Assessment of Disease-Related Therapeutic Protein Drug-Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis, PMID: 26412221

Next-Generation Therapeutics for IBD, PMID: 26031830

Next-Generation Therapeutics for Inflammatory Bowel Disease, PMID: 27461274

Anti-trafficking agents in the treatment of inflammatory bowel disease, PMID: 31567498

Emerging Therapies for Inflammatory Bowel Disease, PMID: 30374806

Interfering with leukocyte trafficking in Crohn's disease, PMID: 31327399

Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts, PMID: 30165490

Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease, PMID: 29767705

Leukocyte Anti-Trafficking Strategies: Current Status and Future Directions, PMID: 28147349

Anti-Adhesion Therapies in Inflammatory Bowel Disease-Molecular and Clinical Aspects, PMID: 28804488

Current and emerging biologics for ulcerative colitis, PMID: 25547087

Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis, PMID: 25761174

Emerging treatments for ulcerative colitis: a systematic review, PMID: 28503977

Advances in the development of new biologics in inflammatory bowel disease, PMID: 27366024

Fungal infections following treatment with monoclonal antibodies and other immunomodulatory therapies, PMID: 31843275

Impact of various central endoscopy reading models on treatment outcome in Crohn's disease using data from the randomized, controlled, exploratory cohort arm of the BERGAMOT trial, PMID: 32464142

The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews, PMID: 27306074

Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases, PMID: 25110260

Return to sender: Lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis, PMID: 31108158

Review article: anti-adhesion therapies for inflammatory bowel disease, PMID: 24479980

The future of inflammatory bowel disease therapy: where do we go from here?, PMID: 23295705

Antibodies to watch in 2018, PMID: 29300693

Document Download

Research Grade Etrolizumab.pdf